GLP-1 Receptor Agonists: Clinical Trial Considerations

The U.S. Food & Drug Administration (FDA) has accredited sure GLP-1 medicine for commercialization and use, together with liraglutide (Victoza®), semaglutide (Ozempic®, Wegovy®), and tirzepatide (Mounjaro®, Zepbound®). Although these medicine are FDA-approved to deal with particular situations, comparable to weight problems or kind 2 diabetes, analysis research for potential extra makes use of and situations, past weight problems and diabetes, are underway.

Research for extra makes use of is being carried out as there’s perception within the medical and scientific communities that these medicine could help in treating a variety of situations, comparable to hypertension, habit, coronary heart failure, kidney illness, sleep apnea, osteoarthritis, and probably Parkinson’s and Alzheimer’s illness. Researchers are at the moment exploring the potential of GLP-1 medicine to deal with these situations, and medical trials are ongoing. An inventory of GLP-1 targeted medical research is out there at ClinicalTrials.gov.

Drug Approval Process

Until a GLP-1 drug is accredited by the FDA for a brand new affected person inhabitants or new situation, any prescription for the usage of the drug for a situation or with a affected person that isn’t contemplated throughout the FDA-approved labeling is and is taken into account “off label” prescribing. Drug producers could not promote the drug for an “off-label” use. Any prescription of a drug for an “off-label” use should be made on the sole discretion {and professional} medical judgment of the prescribing doctor.  The off-label standing could influence some affected person protection and declare reimbursement determinations though the drug is accredited by FDA for a minimum of one different (label) use.  

Applicants should submit a New Drug Application (NDA) to the FDA to obtain FDA approval to market a drug for a brand new supposed use or indication to be used, comparable to a brand new particular affected person inhabitants. Before a drug can legally be marketed for a brand new supposed use or indication to be used (e.g., new affected person inhabitants), the protection and efficacy of the brand new supposed use or indication to be used should be demonstrated by means of well-controlled medical trials.

New medicine should sometimes cross by means of three medical trial phases earlier than being thought of by FDA for approval:

• Phase 1 – Small variety of healthy take a look at topics; assessing security and dosage.
• Phase 2 – Larger group of take a look at topics with the illness or situation being studied; evaluating effectiveness and security.
• Phase 3 – Larger group of take a look at topics usually throughout a number of places; confirming effectiveness, monitoring unintended effects, and evaluating the brand new therapy to plain of care.
  • Phase 3 research are sometimes designed as randomized, double-blind, placebo-controlled trials, which implies that neither the contributors nor the researchers know which therapy every participant is receiving.

Conducting medical trials takes appreciable time, effort, and assets. Obtaining drug approval by way of the normal NDA pathway can take years (usually as much as 15 years) and price hundreds of thousands of {dollars}.

Clinical Trial Design for Accelerated Drug Approval

Despite the thrilling potential for GLP-1 medicine to deal with a spread of situations past weight problems and diabetes, acquiring drug approval for brand new indications to be used stays a frightening job because of the appreciable time, effort, and assets required to conduct the mandatory medical trials. Fortunately, FDA affords an accelerated drug approval pathway which may be useful for candidates growing new makes use of and indications for already accredited medicine, comparable to FDA-approved GLP-1 medicine.

The 505(b)(2) NDA pathway supplies a streamlined route for drug approval that permits FDA to contemplate pre-existing information when reviewing an NDA for a brand new indication of use — even when the applicant didn’t develop the information themselves.

This pathway accelerates the approval course of and reduces prices as a result of candidates could embody information from exterior research to ascertain the protection and efficacy of the already FDA-approved lively ingredient. Applicants should nonetheless provide their very own information, comparable to analysis outcomes, that help the brand new indication to be used, however they could additionally depend on current information demonstrating what’s already recognized concerning the beforehand accredited drug.

When designing medical trials to help new indications to be used of FDA-approved GLP-1s, candidates ought to:

1. Consider methods to leverage current information (e.g., public information or earlier FDA findings) to cut back the dimensions, scope, timeline, and price of improvement.
2. Conduct complete literature evaluations to search out publicly out there information.
3. Develop research which are supposed to efficiently bridge what’s already recognized concerning the drug and the proposed modification to the drug.
4. Work carefully with the FDA by way of conferences such because the pre-investigational new drug (IND) part conferences, Type C conferences, and pre-NDA conferences to realize the FDA’s enter concerning the scope of its proposed research.
5. Carefully consider exclusivity intervals and patenting/advertising and marketing methods.

 Because of the elevated necessities relevant to these kinds of research, it’s crucial that firms conducting these research rigorously construction their drug improvement packages to make sure that all research are appropriately capturing the extent of element and thoroughness which FDA would require when reviewing an NDA. It is crucial that these firms preserve a powerful working relationship with FDA all through this course of; keep knowledgeable concerning any new steering which will influence this distinctive drug class; pay cautious consideration when negotiating medical trial agreements to make sure all medical information, info, and outcomes are protected, confidential, and owned by the sponsor; and set up robust compliance packages to make sure that the corporate, as a medical trial sponsor, meets all high quality system and different FDA necessities.

For extra assets on GLP-1 medicine and the way they’ll change the Health Care & Life Sciences and Technology industries, click on right here to learn the opposite articles in our sequence.

Foley is right here that will help you handle the short- and long-term impacts within the wake of regulatory modifications. We have the assets that will help you navigate these and different necessary authorized issues associated to enterprise operations and industry-specific points. Please attain out to the authors, your Foley relationship accomplice, our Health Care & Life Sciences Sector, or to our Innovative Technology Sector with any questions.